powerpoint presentation on virus

An Introduction to Viruses

Jul 24, 2014

1.02k likes | 1.96k Views

An Introduction to Viruses. Lecturer Dr Ashraf Khasawneh Department of Biomedical Sciences. Virus infections are Universal ……. Introduction to Virology. A virus is an obligate intracellular parasite containing genetic material surrounded by protein

Share Presentation

• california encephalitis viruscoronavirushantavirusinfluenza virus
• hav hepatitis b virus
• hiv human t
• capsid envelope
• step growth
• mosaic virus

Presentation Transcript

An Introduction to Viruses Lecturer Dr Ashraf Khasawneh Department of Biomedical Sciences

Virus infections are Universal …….

Introduction to Virology • A virus is an obligate intracellular parasite containing genetic material surrounded by protein • Virus particles can only be observed by an electron microscope

Introduction to Virology • Recognizing the shape, size, and structure of different viruses is critical to the study of disease • Viruses have an inner core of nucleic acid surrounded by protein coat known as an envelope • Most viruses range in sizes from 20 – 450 nanometers

Viral Properties • Viruses are inert (nucleoprotein ) filterable Agents • Viruses are obligate intracellular parasites • Viruses cannot make energy or proteins independent of a host cell • Viral genome are RNA or DNA but not both. • Viruses have a naked capsid or envelope with attached proteins • Viruses do not have the genetic capability to multiply by division. • Viruses are non-living entities

Virus vs. cells Property Viruses Cells Type of nucleic acid DNA or RNA DNA and RNA Proteins Few Many Lipoprotein membrane Enveloped Cell membrane present in present in some viruses all cells Ribosomes Absent Present Mitochondria Absent Present in eukaryotic cells Enzymes None or few Many Multiplication by binary fission No Yes (most cells)

Viruses are Ultramicroscopic Koneman et al. Color Atlas and Textbook of Microbiology 5th Ed. 1997

The size of viruses

VIRAL STRUCTURE – SOME TERMINOLOGY • virus particle = virion • protein which coats the genome = capsid • capsid usually symmetrical • capsid + genome = nucleocapsid • may have an envelope

Virion • The complete infectious unit of virus particle • Structurally mature, extracellular virus particles.

Nucleic acid Capsid Envelope protein Membrane protein Viral envelope** Nucleocapsid Viral Structure - Overview Spike protein Fig 1. Schematic overview of the structure of animal viruses ** does not exist in all viruses

Distinguishing characteristics of viruses • Obligate intracellular parasites • Extreme genetic simplicity • Contain DNA or RNA • Replication involves disassembly and reassembly • Replicate by "one-step growth”

Naming viruses • No taxa above Family (no kingdom, phylum, etc) • Classified based on structures, size, nucleic acids, host species, target cells. • 19 families of animal viruses (6 DNA, 13 RNA) • Family name ends in – viridae • Subfamily ends in — virinae • Genus name ends in – virus • Species • Example • Family – Herpesviridae • Subfamily - Herpesvirinae • Genus – Simplex virus • Common name – herpes virus (Herpes simplex virus I (HSV-I) • Disease – fever blisters, cold sores

How are viruses named? • Based on: - the disease they cause poliovirus, rabies virus - the type of disease murine leukemia virus - geographic locations Sendai virus, Coxsackie virus - their discovers Epstein-Barr virus - how they were originally thought to be contracted dengue virus (“evil spirit”), influenza virus (the “influence” of bad air) - combinations of the above Rous Sarcoma virus

Virus particle = virion

5 BASIC TYPES OF VIRAL STRUCTURE nucleocapsid icosahedralnucleocapsid lipid bilayer ICOSAHEDRAL ENVELOPED ICOSAHEDRAL helicalnucleocapsid COMPLEX nucleocapsid lipid bilayer glycoprotein spikes = peplomers HELICAL ENVELOPED HELICAL

Viral Structure • Varies in size, shape and symmetry • 3 types of capsid symmetry: • Cubic (icosahedral) • Has 20 faces, each an equilateral triangle. Eg. adenovirus • Helical • Protein binds around DNA/RNA in a helical fashion eg. Coronavirus • Complex • Is neither cubic nor helical eg. poxvirus

VIRAL STRUCTURE (virion) Protect genome during passage from one cell to another Aid in entry process Package enzymes for early steps of infection

CAPSID STRUCTURE Morphological types 1. Helical capsid • Rod-shaped capsomers • Coil around hollow center • Nucleic acid is kept inside – wound-up within tube (Helix )

Morphological types Helical – capsid surrounds DNA like hollow tube Ex: Influenza , measles, rabies (enveloped)

Helical symmetry

Helical symmetry How to assemble

Helical symmetry In 1955, Fraenkel, Conrat, and Williams demonstrated that tobacco mosaic virus (TMV) spontaneously formed when mixtures of purified coat protein and its genomic RNA were incubated together. TMV, a filamentous virus

Morphological types 2. icosahedral • 20-sided with 12 corners • Vary in the number of capsomers • Each capsomer may be made of 1 or several proteins • Some are enveloped PROTOMER

Icosahedral capsids a) Crystallographic structure of a simple icosahedral virus. b) The axes of symmetry

Cubic or icosahedral symmetry

5-FOLD 3-FOLD 2-FOLD ICOSAHEDRAL SYMMETRY

ICOSAHEDRAL SYMMETRY

CAPSOMER ICOSAHEDRAL SYMMETRY = PENTON (pentamer)

CAPSOMER CAPSOMER = HEXON ICOSAHEDRAL SYMMETRY = PENTON

12 PENTONS 240 HEXONS Adenovirus

Enveloped helical virus Enveloped icosahedral virus

Helical • California Encephalitis VirusCoronavirusHantavirusInfluenza Virus (Flu Virus)Measles Virus ( Rubeola)Mumps VirusPara influenza VirusRabies VirusRespiratory Syncytial Virus(RSV)

Adeno-associated Virus (AAV)AdenovirusB19Coxsackievirus - ACoxsackievirus - BCytomegalovirus (CMV)Eastern Equine Encephalitis Virus (EEEV)EchovirusEpstein-Barr Virus (EBV)Hepatitis A Virus (HAV)Hepatitis B Virus (HBV)Hepatitis C Virus (HCV)Hepatitis Delta Virus (HDV)Hepatitis E Virus (HEV) Herpes Simplex Virus 1 (HHV1)Herpes Simplex Virus 2 (HHV2)Human Immunodeficiency Virus (HIV)Human T-lymphotrophic Virus (HTLV)Norwalk VirusPapilloma Virus (HPV)Polio virusRhinovirusRubella VirusSaint Louis Encephalitis VirusVaricella-Zoster Virus (HHV3)Western Equine Encephalitis Virus (WEEV)Yellow Fever Virus Icosahedral

Complex viruses • Have additional or special structures • Examples: • Poxviruses – lack normal capsid – instead, layers of lipoprotiens and fibrils on surface cross section surface view

A bacteriophage • A bacteriophage is any one of a number of viruses that infect bacteria. They do this by injecting genetic material, which they carry enclosed in an outer protein capsid. The genetic material can be ssRNA, dsRNA, ssDNA, or dsDNA ('ss-' or 'ds-' prefix denotes single-strand or double-strand) along with either circular or linear arrangement.

Phage - viruses have a polyhedral head, helical tail and fibers for attachment.

Classification of viruses • Nucleic acid • Capsid • Presence of envelope • Replication strategy

CLASSIFICATIONNUCLEIC ACID • RNA or DNA • segmented or non-segmented • linear or circular • single-stranded or double-stranded • if single-stranded RNA • is genome mRNA (+) sense or complementary to mRNA (-) sense

ENVELOPE • OBTAINED BY BUDDING THROUGH A CELLULAR MEMBRANE (except poxviruses) • POSSIBILITY OF EXITING CELL WITHOUT KILLING IT • CONTAINS AT LEAST ONE VIRALLY CODED PROTEIN • ATTACHMENT PROTEIN • LOSS OF ENVELOPE RESULTS IN LOSS OF INFECTIVITY

Properties of naked viruses • Stable in hostile environment • Not damaged by drying, acid, detergent, and heat • Released by lysis of host cells • Can sustain in dry environment • Can infect the GI tract and survive the acid and bile • Can spread easily via hands, dust, fomites, etc • Can stay dry and still retain infectivity • Neutralizing mucosal and systemic antibodies are needed to control the establishment of infection

Naked viruses( Non Enveloped ) • Adeno-associated Virus (AAV)AdenovirusB19Coxsackievirus - ACoxsackievirus - BEchovirusHepatitis A Virus (HAV)Hepatitis E Virus (HEV)Norwalk Virus

The Baltimore classification system Based on genetic contents and replication strategies of viruses. According to the Baltimore classification, viruses are divided into the following seven classes: 1. dsDNA viruses 2. ssDNA viruses 3. dsRNA viruses 4. (+) sense ssRNA viruses (codes directly for protein) 5. (-) sense ssRNA viruses 6. RNA reverse transcribing viruses 7. DNA reverse transcribing viruses where "ds" represents "double strand" and "ss" denotes "single strand".

Virus Classification - the Baltimore classification • All viruses must produce mRNA, or (+) sense RNA • A complementary strand of nucleic acid is (–) sense • The Baltimore classification has + RNA as its central point • Its principles are fundamental to an understanding of virus classification and genome replication, but it is rarely used as a classification system in its own right

Viral genome strategies • dsDNA (herpes, papova, adeno, pox) • •ssDNA (parvo) • •dsRNA (reo, rota) • •ssRNA (+) (picorna, toga, flavi, corona) • •ssRNA (-) (rhabdo, paramyxo, orthomyxo, • bunya, filo) • •ssRNA (+/-) (arena, bunya) • •ssRNA (+RTase) (retro, lenti)

Sub-viral agents • Satellites • Contain nucleic acid • Depend on co-infection with a helper virus • May be encapsidated (satellite virus) • Mostly in plants, can be human e.g. hepatitis delta virus • If nucleic acid only = virusoid • Viroids • Unencapsidated, small circular ssRNA molecules that replicate autonomously • Only in plants, e.g. potato spindle tuber viroid • Depend on host cell polII for replication, no protein or mRNA • Prions • No nucleic acid • Infectious protein e.g. BSE

Viroids & Prions • Viroids • ss RNA genome and the smallest known pathogens. • Affects plants • Prions • Infectious particles that are entirely protein. • No nucleic acid • Highly heat resistant • Animal disease that affects nervous tissue • Affects nervous tissue and results in • Bovine spongiform encepahltits (BSE) “mad cow disease”, • scrapie in sheep • kuru & Creutzfeld-Jakob Disease (CJD) in humans

• More by User

An Introduction to the Viruses

An Introduction to the Viruses. Viral Components. All viruses have capsids- protein coats that enclose & protect their nucleic acid Viruses may have a membrane envelope Nucleic acid genome: may be dsDNA, ssDNA, ssRNA, dsRNA. Size Comparison of Viruses. Viral Taxonomy.

325 views • 14 slides

INTRODUCTION TO VIRUSES AND THEIR STRUCTURE:

INTRODUCTION TO VIRUSES AND THEIR STRUCTURE: . PETER H. RUSSELL, BVSc, PhD, FRCPath, MRCVS Department of Pathology and Infectious Diseases, The Royal Veterinary College, Royal College Street, London NW1 OTU. E-mail Web site. Objectives Students should be able to:.

263 views • 15 slides

Introduction to Herpes Viruses

Introduction to Herpes Viruses. Hugh B. Fackrell Filename: Herpes1.ppt [email protected]. Herpes Viruses. Group characteristics Herpes simplex 1 Herpes simplex 2. VP26 Assembly in HSV-1 Capsid. Herpes Virus Outline. Structure Classification Multiplication Clinical manifestations

1.33k views • 41 slides

INTRODUCTION TO VIRUSES

INTRODUCTION TO VIRUSES . Viruses They are the non-cellular form of life. A virus is an obligate intracellular parasite containing genetic material surrounded by protein. Virus particles can only be observed by an electron microscope

527 views • 25 slides

An Introduction to Marine Viruses

An Introduction to Marine Viruses . What Is a Virus?. Virus Size & Structure. 1 Micron. Chlamydia. Pox virus. Herpes virus. Influenza Virus. Bacterium ( Staphyllococcus aureus ). Picornavirus (polio). Relative size of viruses and bacteria. Microbial Loop. CO2. DOC.

1.49k views • 16 slides

AN INTRODUCTION TO:

TECHNICAL. GUIDELINES. from the leading resource for education and information in the repair industry. ICRI Technical Guideline No. 210.4-2009. AN INTRODUCTION TO:. Evaluation.

176 views • 6 slides

An Introduction to Viruses. Chapter 6. 6.1 The Search for elusive viruses. Leeuwenhoek’s microscope was extremely important in discovering small life forms But there was a limit to magnification

757 views • 59 slides

Introduction to the Viruses:

Introduction to the Viruses:. General properties of viruses: 1-They are very small in size , from 20-300  m . 2-They contain one kind of nucleic acid ( RNA or DNA ) as their genome . 3-They are metabolically inert because they do not possess

946 views • 17 slides

VIROLOGY An Introduction to the Viruses

VIROLOGY An Introduction to the Viruses. By Prof. Mohamed I. Bassyouni. General properties of viruses.

781 views • 50 slides

Virology Introduction to viruses

418 views • 19 slides

TECHNICAL. GUIDELINES. from the leading resource for education and information in the repair industry. ICRI Technical Guideline No. 320.6-2012. AN INTRODUCTION TO:. Repair Materials and Methods . Guide for Evaluation and Repair of Unbonded Post-Tensioned Concrete Structures .

461 views • 6 slides

TECHNICAL. GUIDELINES. from the leading resource for education and information in the repair industry. ICRI Technical Guideline No. 210.3-2004. AN INTRODUCTION TO:. Evaluation. Guideline for Using In-Situ Tensile Pull-Off Tests to Evaluate Bond of Concrete Surface Materials. Formerly 03739.

224 views • 6 slides

R1 Introduction to Viruses

Section R Viruses R1 Introduction to Viruses R2 Bacteriophages R3 DNA Viruses R4 RNA Viruses. R1 Introduction to Viruses. Viruses Virus genomes Replication strategies Virus Virulence. Viruses-I.

664 views • 33 slides

TECHNICAL. GUIDELINES. from the leading resource for education and information in the repair industry. ICRI Technical Guideline No. 120.1-2009. AN INTRODUCTION TO:. Safety. Guidelines and Recommendations for Safety in the Concrete Repair Industry.

385 views • 6 slides

An Introduction to the Viruses. Chapter 6. The Search for the Elusive Virus. ______________ postulated that rabies was caused by a virus (1884) Ivanovski and Beijerinck showed a disease in tobacco was caused by a virus (1890s) 1950s virology was a multifaceted discipline

952 views • 74 slides

Introduction to Viruses

Introduction to Viruses. The student should be able to. Define the structure of viruses Describe the importance of structure for transmission Classif y the viruses List the steps in viral replication List at least two virus attachment protein and receptor

909 views • 75 slides

BioEd Online. Introduction to Viruses. By Christine Herrmann, PhD. Courtesy of B.V.V. Prasad. BioEd Online. What Are Viruses?. Viruses are very small (10 – 400nm). not cells. a genome surrounded by a protective protein coat. infectious.

450 views • 18 slides

An Introduction to

An Introduction to. Washington Green Schools. Is a voluntary, statewide, web-based program your school can use to: Reduce its carbon footprint Reduce campus operating costs Provide students with hands-on experience & education about the environment. The Mission.

456 views • 24 slides

TECHNICAL. GUIDELINES. from the leading resource for education and information in the repair industry. ICRI Technical Guideline No. 130.1R-2009. AN INTRODUCTION TO:. Procurement Methods. Guide for Methods of Measurement and Contract Types for Concrete Repair Work. Formerly 03735.

174 views • 6 slides

206 views • 18 slides

177 views • 15 slides

Researched by Consultants from Top-Tier Management Companies

Powerpoint Templates

Icon Bundle

Kpi Dashboard

Professional

Business Plans

Swot Analysis

Gantt Chart

Business Proposal

Marketing Plan

Project Management

Business Case

Business Model

Cyber Security

Business PPT

Digital Marketing

Digital Transformation

Human Resources

Product Management

Artificial Intelligence

Company Profile

Acknowledgement PPT

PPT Presentation

Reports Brochures

One Page Pitch

Interview PPT

All Categories

Top 25 Virus PowerPoint Templates To Beat the Invisible Threat

Gunjan Gupta

Viruses are curious little creatures. These tiny tagalongs aren’t exactly living per se, but they are not inanimate either. They’ve replicated themselves into multiple forms both fatal and non-fatal in billions of years and continue to do so even today. These beings have a long trail of history attached to their evolution and perhaps even had a hand or a squishy-squashy protein coating- in helping them mutate and become ever so dangerous. So, much so that they have become a threat to human existence.

In the recent turn of events, where the global pandemic Corona virus popularly known as Covid-19 is on a rise bringing along a chain of untimely deaths and mourns throughout the world, it is necessary to have a much closer look at these tiny microbial compounds. 

If you are also curious to know about these tiny, yet not-so-tiny beings, their origination, evolution, health effects, and more, well tag along.

The evolutionary history of viruses is a fascinating, yet debatable topic for virologists and cell biologists, because of their diverse nature. As such it is a constant struggle to classify these entities and relate their existence to the human tree of life. They may be genetic elements or previously living organisms evolving as parasites. Constant research is going on these topics. 

So, to support the vision of virologists and help them with their never-ending search, SlideTeam professionals have designed a few virus PowerPoint templates that will resolve some of the basic queries about these “microbes”. Each of these templates are apt to unfold new facts about viruses, and their existence, endangering the lives of the only living species in the world- us HUMANS!

Virus Templates to Download and Use 

We are well aware that viruses are diverse in nature and so is their biological composition. Some have RNA genomes while some are made up of DNA genomes. This template can be used to explain the structure as well as the replication strategies of these microbes. It can also be used to explain the dizzying array of functions and health effects of viruses on human health as well as the research conducted on it. Some interesting facts about coronavirus and its genetic mutation can be unfolded in this section and presented to get a better understanding of the origin of this virus. These may include the 10-time mutation study of the virus, posing the biggest threat to humanity. Let alone, various other studies and scientific evidence can be presented by healthcare professionals by utilizing this interesting layout that can be customized. 

  Template 2

Science is the be-all and end-all of our findings. With the outbreak of the world deadliest virus ‘Coronavirus’, creating havoc in the lives of billions of people, this is a classic template that can be used by researchers and scientists to present their interesting studies. The biological composition of various viruses and their origination can be outlined and presented. This template can also be used by healthcare professionals to explain some of the symptoms and ill effects of various viruses. Not all the viruses are deadliest and so information about its various types can be elaborated on in this template. It also comes in handy for biological students to present their research findings after careful analysis of viruses, thus helping them impress their teachers. 

Download Virus Science PowerPoint Templates 

The Internet is flooded with false information about coronavirus and its outbreak. This template can be used by healthcare professionals to create awareness and stop the spreading of false rumors. It can also be used to present the recent worldwide stats of the infection as well as some safety measures that can be adopted by the masses to keep the spread in check. The science behind various viruses can be outlined in this template, to increase the overall understanding of the viewers. Nonetheless, it is an apt design for biomedical students to present their results, findings, and reviews on various viruses to advise medical practitioners. 

Download Virus Science PowerPoint Templates And PowerPoint Background

Influenza is a major public health concern as it infects nearly 5-10% of the global population annually. Hence, there is a need to understand the molecular structure of this virus to reduce its strain on human health. Our professionally designed template can help you give a brief about how the virus multiples, infects, and how to combat infection, making it extremely useful for virologists and cell biologists. Additionally, it can be used to present researchers on few vaccines formulated to reduce the risk of influenza as well as the treatment prescribed. This design is fully adaptive to your needs so feel free to make any changes as you like depending upon your field of interest. 

Download Structure Of The Influenza Virion Medical Images For PowerPoint

This template is ideal for a biology class to show and share important information on various viruses, their origin, infections caused by them, and others. The theme is formal and hence can be used to demonstrate any topic in science class and submit an assignment as well. Doctors, nurses and paramedical staff can also utilize this template to present the information on vaccine reactions which may happen to patients, thus creating awareness. A lot of studies conducted on viruses is also the topic this slide caters to. Additionally, such medical templates are apt for drug health lessons in ordinary schools, colleges, and medical universities. All of these characteristics make this a universally efficient template. Hence, any individual can download it to present his topic in a comprehensive manner. 

Download Virus Microorganism Geographical PowerPoint Templates And PowerPoint Backgrounds

The outbreak of coronavirus throughout the world has become one of the most notorious events of the decade, if not the current century. We can say that we have welcomed a new decade with a catastrophe of death and mourning. Since, this pandemic is nothing short of deadly, taking away lakhs of lives, every bit of information helps a lot. This virus danger template can help you create awareness on this global pandemic. It is a virus and microorganisms based theme template to put everything topic related to the context. The control and prevention of this disease can be the pillars of your talking points after utilizing this presentation theme. Also, there is a consistency in the theme of this template and includes font size that can be easily viewed from a distance. Thus, making it an efficient design that can help you present great presentations on science, biology, virology, and other related fields. 

Download Virus Danger Globe PowerPoint Templates And PowerPoint Backgrounds

This template is designed for HIV and Aids doctors, students, academicians, and other professionals looking for comprehensive designs to create presentations for their universities, hospitals, seminars, and several others. HIV and Aids is a very important topic for medical practitioners to get acquainted with. This template can help you showcase important information on Aids and the causes of its spread. This is also a great design for medics and professionals to convey their thoughts on the topic, thus helping them become better communicators. 

HIV Virus Medical PowerPoint Templates And PowerPoint Backgrounds

The mechanism of HIV entry to the host cell can be explained with this pre-designed template. This layout focuses on the design needs of medical professionals to give a descriptive view of the topic. It is apt for doctors, nurses, paramedics, researchers, academicians, and others working in the field of HIV Aids and its transmission. This content-ready template enables you to deliver great presentations revolving around the topic of HIV with minimum effort and maximum effect. Its simple to download layout requires only a few clicks to get you ready for your upcoming medical presentations. Hence, convey your thoughts and ideas on HIV with this template, that is subjected to numerous alterations, depending upon the requirements of the user. 

Download HIV Attachment To Target T Cell Medical Images For PowerPoint

Classification and explanation of the nomenclature of viruses is a breeze with this template. It is specifically designed for paramedical staff to discuss their views on Hepatitis B and how it affects the liver of the infected patient. Since almost 1 million people die every year because of chronic hepatitis B infection which is preventable and treatable this template comes in very handy to present the important details and facts. Also, new perspectives on the life cycle of hepatitis B can be thoroughly explained in medical universities with this thoughtfully designed template. Since this template is versatile and flexible it is easily adaptable to all your needs and requirements. All you have to do is click on the download button and use it extensively. 

Download Hepatitis B Virus Medical Images For PowerPoint

Template 10

This template can be used to explain the microscopic view and nomenclature of the Papillomavirus or HPV infection. It can also be used to understand its preventive measures, causes, and treatment making it an ideal fit for doctors to give a deeper understanding of the topic. Hospitals and medical universities can utilize this template to teach and train students and staff members. This slide acts as a very good teaching tool as the viewers are able to get a thorough understanding of health care issues, proposed safety measures, reasons for infections, and similar other topics. Additionally, the pre-designed layout of this template showing the entire structure of the virus makes it extremely easy to deliver great medical presentations with minimum effort. 

Download Human Papilloma Virus Medical Images For PowerPoint

Template 11

This template can be used by doctors, medical universities, researchers, virologists, cell biologists, and others to present a thorough understanding of the structure of HIV and how it leads to a non-treatable infection. It showcases two types of infection latent and active and how the synthesis happens. Since this template is so descriptive designed using apt color scheme, it is efficient enough to grab this immediate attention of the viewer. You can either use this template in conjunction with your presentation or as a single entity as it is complete in itself. 

Download Latent And Active Infection Of T Cell By HIV Medical Images For PowerPoint

Template 12

Adenovirus is ubiquitous viruses that cause various pediatric illnesses including common cold. They can also cause gastrointestinal, ophthalmologic, neurologic, and genitourinary symptoms. This template has especially been designed for paramedics and cell biologists to explain the basic structure of adenovirus and its prevention. While illness caused due to viruses have become quite common, having a thorough understanding of the illness is important. This template can be used in a discussion session needing to study the causes of viral growth, its production, and other aspects. Due to its attractive layout, it never fails to impress any audience. 

Download Adenovirus Morphology Medical Images For PowerPoint

Template 13

This is yet another adenovirus template that is suitable to discuss the structure and movement of viruses in the human body. You can also explain the causes of its growth, infection and expansion with this template that is fully adaptable to one’s needs and requirements. Biological experiments and genetic engineering projects can also be presented using this template that is fully responsive. 

Download Adenovirus Medical Images For PowerPoint

Template 14

Download this Leukemia template for your upcoming medical presentations. This template is specifically designed keeping in mind the needs of medical practitioners, healthcare professionals, and pathologists. So, you can easily edit it with your own content as this template uses royalty-free images. Apart from this, the template design can be used as a background of your presentation on leukemia, symptoms, causes, types, diagnosis, and treatment. Therefore grab this multifunctional PPT now to convey your information on leukemia cancer impressively. 

Download Leukemia Science PowerPoint Templates And PowerPoint Backgrounds

Template 15

Another family of virus Hepatitis A can be influentially explained with this pre-designed template. Doctors, nurses, and other medical staff members can use it to create presentations for universities, hospitals, and other places depending upon their needs and requirements. It is also a good explanation tool for conferences and medical counseling sessions conducted in hospitals. The causes, vaccine reactions, side effects of the vaccine, diagnosis, treatment, and other aspects can be discussed efficiently with this neatly-designed template. The pre-designed elements of this template make your presentation work quick and a lot more convenient.

Download Hepatitis A Virus Medical Images For PowerPoint

Template 16

Showcase important information related to Herpes Simplex Virus using this slide. Explain its causes, risk factors, symptoms, vaccine, diagnosis, treatment, and other important aspects. Since this slide caters to the biology of viruses it will act as a great teaching tool in schools, medical universities, hospitals, and other places. Apart from this, it can be used by any medical practitioner and cell biologists depending upon what their project commands. 

Download Herpes Simplex Virus Medical Images For PowerPoint

Template 17

This pre-made template can be used to present amazing presentations on topics like virology, immunization, vaccination, and others. This template specifically targets Respiratory Syncytial Virus hence it can be used to give a thorough explanation of this virus, its types, symptoms, diagnosis and other aspects making it highly useful for the medical practitioners. 

Download Respiratory Syncytial Virus Medical Images For PowerPoint

Template 18

This presentation design is perfect for presenting strategies on the stop of growth and spreading of infection in humans. You can outline the entire structure of Measles and the infection caused by it using this template. Doctors can also use this template to educate their patients about Measles and prescribe an effective treatment for it. Nonetheless, the layout of this slide is designed professionally hence it is an ideal fir for medical students as well. 

Download Measles Virus Medical Images For PowerPoint

Template 19

Such templates are great for providing health lessons on various viruses, their causes, symptoms, and the like. They can be used by medical professionals, biology teachers, medical universities, and others as a contribution to preventing infections from spreading by creating awareness. Since this template is pre-designed it will function as a great tool to present medical presentations. 

Download Arena Virus Particle Structure Medical Images For PowerPoint

Template 20

Give a descriptive presentation on the highly contagious and deadly disease Smallpox using this slide. Showcase the structure of variola virus and its infection that leads to smallpox in humans. You can also present the history and evolution of this virus along with its treatment. Use it in conjunction with your medical presentation to create an impact. The high-resolution images used in each of the slides act as great teaching tools for educators, academicians, paramedical staff, and others.  

Download Smallpox Virus Medical Images For PowerPoint

Template 21

Many infectious diseases are becoming fatal among human beings because of the overgrowth of viruses. One such virus is the rubella virus causing red rashes throughout the body. This template aims at giving an overview of rubella, its causes, symptoms, and others. Thus, making it a highly resourceful design for your medical presentations. 

Download Rubella Virus Medical Images For PowerPoint

Template 22

We are bombarded with new infections every year some which are deadly and some which are not. This presentation aims at targeting a similar virus and its infections known as the RSV virus causing respiratory issues in children. The descriptive layout of this template makes it apt for presenting various medical presentations that are impressive and convince enough. These templates are specially designed to ease the work of the user by providing ready-made design and aesthetics. 

Download RSV Virus Medical Images For PowerPoint

Template 23

Mimivirus questions our understanding that viruses are small as this the largest and most complex virus ever found. This template can be used by presenters to explain the evolution, discovery, and analysis of mimivirus both from the scientific and medical perspectives. It showcases the complex structure of mimivirus and its characteristics which defy the conventional definitions of life. Using this template will help you explain the mimivirus more descriptively, thus making it a great template for your presentations. 

Download Mimi Virus Particle Structure Medical Images For PowerPoint

Template 24

This template shows the entire lifecycle of HIV and its replication, thus making it an outstanding explanation tool. This template is fully functional for doctors, medical universities, teachers, academicians, etc. looking to present important information on HIV and its infection. It is also a great tool to create awareness about this particular virus among the masses so that necessary steps can be taken to keep its spread in check. Apart from this biological experiment lab and genetic engineering projects can also use this template in whichever way they prefer. 

Download Replication Cycle Of Human Immunodeficiency Virus HIV Medical Images For PowerPoint

Template 25

While the world is battling with a pandemic Coronavirus and its mutated offsprings, we have designed this template to help you present some safety measures that will help fight with this virus, eating up the entire human race slowly and gradually. This template can be used to present information about the virus and safety measures to keep its spread in check like using sanitizers, wearing masks, observing social distancing, washing hands, not touching nose and face, etc. You can also use this template as a background for your presentations related to viruses. 

Download Fight With Virus Medical PowerPoint Templates And PowerPoint Backgrounds

Contemplating the origin of life is a fascinating topic for both scientists and the general public such as you and me. Understanding the evolutionary history of viruses and their life span can surely shed some light on this topic, which is what these 25 virus templates aim for. 

Although there is no clear explanation of the origin of these viruses, these have been present for millions of years among us humans. So, even a little bit of information can make a world of difference here. 

Download these templates to spark a sense of hope in these difficult and dark times where our lives and deaths are dependent on a VIRUS called Coronavirus or COVID 19.

Related posts:

• 10 Best Medical Google Slides Templates For Improving Lives
• Increase The Cohesiveness Of Workplace With Our Top 20 Organizational Culture Presentation Templates for PowerPoint!!
• Top 35 Change Management Templates To Transform Your Business WorkFlow
• 9 Beautiful Color Palettes for Designing Powerful PowerPoint Slides

Liked this blog? Please recommend us

Top 40 Medical, Healthcare Templates for Doctors and Nurses

Top 25 Drugs and Medicines PowerPoint Templates trusted by Medical Professionals

Top 30 Medical PowerPoint Slides for the Soldiers Fighting Against CoronaVirus!

Battling Coronavirus: Dumbledore’s Wise Message Guides Us in These Dark Times

The Complete COVID-19 PPT Presentation: Outbreak & Impact

This form is protected by reCAPTCHA - the Google Privacy Policy and Terms of Service apply.

Digital revolution powerpoint presentation slides

Sales funnel results presentation layouts

3d men joinning circular jigsaw puzzles ppt graphics icons

Business Strategic Planning Template For Organizations Powerpoint Presentation Slides

Future plan powerpoint template slide

Project Management Team Powerpoint Presentation Slides

Brand marketing powerpoint presentation slides

Launching a new service powerpoint presentation with slides go to market

Agenda powerpoint slide show

Four key metrics donut chart with percentage

Engineering and technology ppt inspiration example introduction continuous process improvement

Meet our team representing in circular format

Home PowerPoint Templates PowerPoint Templates Virus Infographics Presentation Template

Virus Infographics Presentation Template

The Virus Infographics Presentation Template features graphics to boost healthcare presentations about infectious diseases. This is a 7 slides PowerPoint deck containing various layout designs to showcase virus-related information. Viruses are parasites that replicate inside living cells at the microscopic level. As the coronavirus pandemic spreads around the world, the discussion around viruses has become a focus point. You can take advantage of the virus infographics template for an overview of microbiological research findings, virus symptoms, prevention, and cure. It is a ready-to-use presentation dedicated to talking about viruses with the help of modern infographics. These infographics include vector-based virus shapes, medical equipment, and prevention options.

The virus infographic theme presents diagrams are available as timelines, core concept, and segmented layout. You can easily replace the text and customize the design of icons to discuss health concerns about viruses. Such as definition of a virus, comparing structure of viruses, discover differences or similarities, historical data, etc. The PowerPoint shapes will help you place everything in context at a glance. For example, use lung infographics to explain how virus attacks and damages lungs. The process diagram is an activity flow that could be used for prevention strategies or recovery afterward. The hand hygiene infographics slide could serve the discussion about effective prevention methods to curb the spread of viruses.

Since influenza, SARS, and COVID-19 continue to emerge and spread across the world. The research on infectious viruses and bacteria has become more valuable. This Virus Infographics Presentation Template will help you create presentation about infectious viruses. The virus slides can be used in several ways to demonstrate different viruses. You can customize the color theme and design of PowerPoint shapes for your minimalist representation of viruses.

You must be logged in to download this file.

Favorite Add to Collection

Details (7 slides)

Supported Versions:

Subscribe today and get immediate access to download our PowerPoint templates.

Related PowerPoint Templates

Incident Report PowerPoint Template

Diabetes Presentation Template

Care Pathway Patient Journey Map Template for PowerPoint

Patient Journey PowerPoint Template

• The Power of mRNA
• Responsibility

News Details

Moderna advances multiple vaccine programs to late-stage clinical trials.

Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints

Expects two more Phase 3 readouts in 2024, including combination vaccine against flu and COVID-19, and vaccine against CMV

Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances programs toward Phase 3 development

Anticipates U.S. launch of vaccine against RSV following FDA approval and ACIP recommendation in 2024

Announces development and commercialization funding agreement with Blackstone Life Sciences for up to $750 million to advance flu program

"Our mRNA platform continues a remarkable track record across our broad vaccine portfolio. Today, we are excited to share that four vaccines in our pipeline have achieved successful clinical readouts across our respiratory, latent and other virus franchises," said Stéphane Bancel, Chief Executive Officer of Moderna. "With five vaccines in Phase 3, and three more moving toward Phase 3, we have built a very large and diverse portfolio addressing significant unmet medical needs. We are focused on execution to further build momentum across our pipeline and business, and to deliver for patients who are impacted by these infectious diseases."

Portfolio Overview

The vaccine portfolio seeks to address infectious diseases that cause considerable health burdens and includes 28 vaccines addressing respiratory, latent and other pathogens.

Latent and Other Vaccine Portfolio

Moderna is advancing five vaccine candidates against viruses that cause latent infections, all of which are in clinical trials. When latent, a virus is present in the body but exists in a resting state, typically without causing any noticeable symptoms. Latent viruses can reactivate and cause clinical symptoms as a person ages, during times of stress or when immunity is compromised. The capacity for latency is a defining feature of members of the Herpesviridae family, including cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV) and Varicella-Zoster virus (VZV).

Cytomegalovirus (CMV)

CMV is the most common infectious cause of birth defects in the U.S. and is responsible for several billion dollars in annual healthcare costs. One in 200 babies in the U.S. are born with a congenital CMV infection, and of those affected, one in five will have severe, life-altering health problems. Possible short- and long-term sequelae of CMV infection include microcephaly, chorioretinitis, seizures, sensorineural hearing loss, cognitive impairment and cerebral palsy. There is currently no approved vaccine to prevent congenital CMV.

CMVictory is a pivotal Phase 3 trial evaluating mRNA-1647 against primary CMV infection in women 16 to 40 years of age. The trial is a randomized, observer-blind, placebo-controlled study designed to evaluate the efficacy, safety and immunogenicity of mRNA-1647. The trial is fully enrolled with approximately 7,300 participants from 290 clinical sites globally.

To date, 50 primary infection cases have accrued and are undergoing confirmation. The first interim analysis for the evaluation of vaccine efficacy, which will be triggered when both 81 confirmed per-protocol cases and 12 median months of safety follow-up have occurred, is expected as early as the end of 2024.

Moderna's CMV vaccine candidate mRNA-1647 has advanced to indication expansion studies in adolescents 9 to 15 years of age and adult transplant patients, both of which have begun enrollment.

Epstein-Barr virus (EBV)

EBV is a major cause of infectious mononucleosis (IM) in the U.S., accounting for more than 90% of IM cases annually. Importantly, EBV and IM are associated with a higher lifetime risk of more serious sequelae including certain cancers such as gastric carcinoma, nasopharyngeal carcinoma and multiple types of lymphoma. The lifetime risk of developing multiple sclerosis (MS) is increased by 32-fold after EBV infection. There is currently no approved vaccine to prevent EBV.

Moderna's EBV vaccine candidates are designed to tackle multiple EBV-associated conditions, including prevention of IM (mRNA-1189) and MS and post-transplant lymphoproliferative disorder, a subcategory of lymphoma in solid organ transplant patients (mRNA-1195) . The Phase 1 trial for mRNA-1189 was designed to test the safety, reactogenicity and immunogenicity of four different dose levels in participants 12 to 30 years of age in the U.S. The randomized, observer-blind, placebo-controlled study showed mRNA-1189 was immunogenic and generally well tolerated across all dose levels. The Company is advancing mRNA-1189 toward a pivotal Phase 3 trial.

The Phase 1 trial for mRNA-1195 was designed to test the safety, reactogenicity and immunogenicity of two drug products at four different dose levels in healthy EBV seropositive participants 18 to 55 years of age in the U.S. The randomized, observer-blind, placebo-controlled study is fully enrolled.

Herpes simplex virus (HSV)

Herpes simplex virus type 2 (HSV-2) infects approximately 13% of adults globally and is the primary cause of genital herpes. There are an estimated four billion people globally infected with HSV, of which 491 million cases are HSV-2. Recurrent genital herpes causes a reduction in quality of life, which antivirals (current standard of care) only partially restore. Moderna expects that if an HSV vaccine candidate could deliver similar efficacy as a suppressive antiviral treatment, compliance with recommended therapy and associated quality of life would improve. There is currently no approved vaccine to treat HSV-2.

The first in human, fully enrolled Phase 1/2 trial of mRNA-1608 is designed to test safety and immunogenicity and to establish a proof-of-concept of clinical benefit in adults 18 to 55 years of age with recurrent HSV-2 genital herpes. The randomized 1:1:1:1, observer-blind, controlled study is fully enrolled with 300 participants in the U.S.

Varicella-Zoster virus (VZV)

Herpes zoster, also known as shingles, is caused by reactivation of latent VZV, the same virus that causes chickenpox. Declining immunity in older adults decreases immunity against VZV, allowing reactivation of the virus from latently infected neurons, causing painful and itchy lesions. Herpes Zoster occurs in one out of three adults in the U.S. in their lifetime and the incidence increases at 50 years of age. There is potential to reach a growing and underserved patient population.

Moderna's VZV vaccine candidate mRNA-1468 has initial data available from a Phase 1/2 trial, which was designed to test safety and immunogenicity in healthy adults 50 years of age and older in the U.S. The randomized 1:1:1:1:1, observer-blind, active-controlled study of mRNA-1468 elicited strong antigen-specific T cell responses at one month after the second dose and was generally well tolerated. Results of the first interim analysis support the further clinical development of mRNA-1468 for the prevention of shingles. Additional results from the ongoing Phase 1/2 study will be available later this year, including persistence data. The Company is planning for a pivotal Phase 3 trial. Norovirus

Enteric viruses, including norovirus, are a leading cause of diarrheal diseases, resulting in significant morbidity and mortality worldwide, particularly among young children and older adults. Norovirus is highly contagious and a leading cause of diarrheal disease globally, associated with 18% of all acute gastroenteritis (AGE), resulting in approximately 200,000 deaths per year and substantial healthcare costs. Given the wide diversity of norovirus genotypes, a broadly effective norovirus vaccine will require a multivalent vaccine design. There is currently no approved vaccine to prevent norovirus.

The randomized, observer-blind, placebo-controlled Phase 1 trial was designed to evaluate the safety, reactogenicity and immunogenicity of trivalent  (mRNA-1403)  and pentavalent  (mRNA-1405) norovirus vaccine candidates in 664 participants 18 to 49 years of age and 60 to 80 years of age in the U.S. An interim analysis showed that a single dose of mRNA-1403 elicited a robust immune response across all dose levels evaluated with a clinically acceptable reactogenicity and safety profile. The Company is advancing mRNA-1403 toward a pivotal Phase 3 trial.

Respiratory Vaccine Portfolio

Moderna's approach to ease the global burden of respiratory infections includes vaccine candidates against major causative pathogens, including SARS-CoV-2, respiratory syncytial virus (RSV) and influenza virus. Respiratory infections are a top cause of death in the U.S. and are particularly harmful to the young, immunocompromised, and older adults who experience more severe illness, greater incidence of hospitalization, and greater mortality than younger adults.

Moderna's respiratory pipeline includes Phase 3 trials for investigational vaccines including a next-generation COVID-19 vaccine, an RSV vaccine, a flu vaccine, and a flu and COVID-19 combination vaccine. The pipeline includes three additional flu vaccine candidates with expanded antigen coverage as well as combination vaccine programs.

Moderna continues to address the needs of the endemic COVID-19 market by focusing on public health efforts to increase vaccination coverage rates to reduce the substantial burden of COVID-19 as well as by advancing next-generation vaccines. The Company's mRNA platform can produce variant-matched vaccines on an accelerated time horizon, consistent with recent U.S. Food and Drug Administration (FDA) comments on the timing of potential strain selection for the fall booster season.

A recent announcement of positive interim results from the NEXTCove Phase 3 trial showed that mRNA-1283 elicited a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2 compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine. mRNA-1283 is designed to be refrigerator-stable and paves the way for a combination vaccine against influenza and COVID-19, mRNA-1083, enhancing the Company's overall respiratory portfolio. This is Moderna's fourth infectious disease vaccine program with Phase 3 data.

Respiratory Syncytial Virus (RSV)

RSV is the leading cause of respiratory illness in young children, and older adults are at increased risk relative to younger adults for severe outcomes. In addition to acute mortality and morbidity, RSV infection is associated with long-term sequelae such as asthma and impaired lung function in pediatric populations, and exacerbation of chronic obstructive pulmonary disease in older adults. Annually, there are approximately two million medically attended RSV infections and 58,000 to 80,000 hospitalizations in children younger than five years old in the U.S. In the U.S., each year there are up to 160,000 hospitalizations and 10,000 deaths in adults 65 years and older due to RSV. Across high-income countries in 2019, RSV caused an estimated 5.2 million cases, 470,000 hospitalizations and 33,000 in-hospital deaths in adults 60 years and older.

Moderna's RSV vaccine candidate, mRNA-1345, is in an ongoing Phase 2/3, randomized, observer-blind, placebo-controlled case-driven trial (ConquerRSV) in adults over 60 years of age. In this study, approximately 37,000 participants from 22 countries were randomized 1:1 to receive one dose of mRNA-1345 or placebo.

Based on positive data from the ConquerRSV trial, Moderna has filed for regulatory approvals for mRNA-1345 for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults over 60 years of age.

The trial met both its primary efficacy endpoints, with a vaccine efficacy (VE) of 83.7% (95.88% CI: 66.1%, 92.2%; p<0.0001) against RSV-LRTD as defined by two or more symptoms, and a VE of 82.4% (96.36% CI: 34.8%, 95.3%; p=0.0078) against RSV-LRTD defined by three or more symptoms. These data were published in the New England Journal of Medicine in December 2023.

A subsequent analysis from the ConquerRSV study with a longer median follow-up duration of 8.6 months (versus 3.7 months in the primary analysis), with a range of 15 days to 530 days, and including subjects from the Northern and Southern Hemispheres was recently presented at the RSVVW'24 conference . In this supplemental analysis, mRNA-1345 maintained durable efficacy, with sustained VE of 63.3% (95.88% CI: 48.7%, 73.7%) against RSV-LRTD including two or more symptoms. VE was 74.6% (95% CI: 50.7%, 86.9%) against RSV-LRTD with ≥2 symptoms, including shortness of breath and 63.0% (95% CI: 37.3%, 78.2%) against RSV-LRTD including three of more symptoms. The stringent statistical criterion of the study, a lower bound on the 95% CI of >20%, continued to be met for both endpoints.

mRNA-1345 has been granted Breakthrough Therapy designation by the FDA for the prevention of RSV-LRTD in adults over 60 years of age. The Company is awaiting regulatory approvals and the U.S. ACIP recommendation in 2024.

Indication expansion studies for mRNA-1345

mRNA-1345 has the potential to protect all vulnerable populations from RSV. Moderna has initiated multiple Phase 3 expansion studies in adults over 50 years of age to evaluate co-administration and revaccination. Additional trials (Phase 1 - Phase 3) have been initiated for high-risk adults, as well as maternal and pediatric populations. Interim data from these studies could be available as early as 2024.

Influenza (Flu)

Worldwide, influenza leads to 3-5 million severe cases of flu and 290,000-650,000 flu-related respiratory deaths annually. Two main types of influenza viruses (A and B) cause seasonal flu epidemics, and the influenza A viruses lead to most flu-related hospitalization in older adults.

The Company has several seasonal influenza vaccine candidates in clinical development. Moderna's seasonal flu vaccine, mRNA-1010 , demonstrated consistently acceptable safety and tolerability across three Phase 3 trials. In the most recent Phase 3 trial (P303), which was designed to test the immunogenicity and safety of an optimized vaccine composition, mRNA-1010 met all immunogenicity primary endpoints, demonstrating higher antibody titers compared to a currently licensed standard-dose flu vaccine. In an older adult extension study of P303, mRNA-1010 is being studied against high dose Fluzone HD ® ; the trial is fully enrolled. The Company is in ongoing discussions with regulators and intends to file in 2024.

Combination Respiratory Vaccines

Moderna's combination vaccine candidates cover respiratory viruses associated with the largest disease burden in the category. The Phase 3 combination study of the Company's investigational combination vaccine against flu and COVID-19 (mRNA-1083) for adults aged 50 years and older is fully enrolled and data are expected in 2024. mRNA-1083 was granted Fast Track designation by the FDA in May 2023.

Commercial Updates

Respiratory viruses in addition to latent and other viruses represent large unmet or underserved medical needs, and the human and economic costs from these infectious diseases highlight the need for effective vaccines. To help address this need, Moderna expects multiple vaccine product launches in the next few years, each with significant addressable markets.

The 2024 global endemic COVID-19 vaccine market alone is estimated by Moderna to be approximately $10 billion. COVID-19 continues to show a high burden of disease, and while COVID-19 hospitalizations remain high relative to RSV and flu, the risks of Long COVID are also becoming better understood. Moderna is focused on improving education and awareness to increase vaccination rates as Long COVID data suggests even traditionally low-risk groups should be vaccinated. Moderna is also working with health authorities to align the timing of COVID-19 and flu vaccine launches to help improve public health.

For RSV, Moderna estimates the peak annual market to be approximately $10 billion. The Company expects a strong RSV vaccine launch into a large market in 2024. As the only mRNA investigational vaccine with positive Phase 3 data, Moderna's RSV vaccine candidate has a strong profile with consistently strong efficacy across vulnerable and older populations, a well-established safety and tolerability profile, and ease of administration with a ready-to-use, pre-filled syringe formulation, which could relieve some of the burden that falls on pharmacies during the fall vaccination season.

An interim analysis from an ongoing time and motion study evaluating differences in preparation time between a pre-filled syringe (PFS) presentation and vaccines that require reconstitution showed that a PFS presentation could relieve some of the burden that falls on pharmacies during the fall vaccination season. Results from this study suggest that pharmacies may be capable of preparing up to four times as many doses of PFS in an hour compared to vaccines requiring reconstitution.

Moderna estimates flu vaccines represent an approximately $7 billion market in 2024. The market is expected to grow with the rise of more effective vaccines and there is an opportunity to expand the market with next-generation premium flu vaccines as well as combination respiratory vaccines, adding increased value to the health ecosystem.

CMV is expected to be a $2-5 billion annual market. With no vaccine currently on the market and a potential vaccine launch in 2026, Moderna could be the first CMV vaccine in multi-billion-dollar latent vaccine market. In addition, EBV has the potential to address and reduce the burden and cost of EBV infection in multiple populations, while VZV provides the opportunity to enter a large and growing market, which could be $5-6 billion annually. The market for norovirus vaccines is similar to that of rotavirus in pediatrics with opportunity to expand into the adult population, and represents a $3-6 billion annual market.

Moderna's vaccine portfolio targets large addressable markets, with an estimated total addressable market (TAM) of $52 billon for Moderna infectious disease vaccines, which includes a respiratory vaccines TAM of more than $27 billion and a latent and other vaccines TAM of more than $25 billion.

Manufacturing

The Company's manufacturing innovation supports expanding commercialization of a diverse pipeline through efficiency and productivity gains. Its mRNA manufacturing platform enables benefits such as quality, speed, scale and cost efficiency across a footprint that broadly includes the manufacture of plasmid, mRNA, lipid nanoparticles, as well as fill/finish and quality control capabilities.

As the Company continues to build its footprint for the future, it is developing an agile global manufacturing network to meet commercial demand and support its growing pipeline. Pre-clinical through commercial manufacturing occurs at the Moderna Technology Center in Norwood, Massachusetts, which remains central to the Company's network. New facilities being constructed in Australia, Canada and the UK are expected to come online in 2025, and drug product capacity is achieved through a flexible contract manufacturing network. Additionally, the Company has purchased and started build-out of a manufacturing site in Marlborough, Massachusetts, to enable commercial scale of its individualized neoantigen therapy program.

By continuing to pioneer new technologies, including advanced robotics, applying AI and other digital solutions, and driving network and capital efficiency, Moderna's manufacturing network is expected to also drive more predictable cost of sales.

Research and Development Investment Strategy

Today's updates provide further evidence that Moderna's mRNA technology platform is working, and with a rate of success higher than industry standard. Looking ahead, research and development will continue to be the Company's top capital allocation priority.

As Moderna looks to create value through the research and development strategy for its vaccine portfolio, it is taking three prioritization parameters into consideration: pipeline advancement, revenue diversification and risk reduction. As part of its strategy, the funding options Moderna considers are self-funding, project financing and partnerships.

Moderna recently entered into a development and commercialization funding agreement with Blackstone Life Sciences to advance the Company's flu program. As part of the agreement, Blackstone will fund up to $750 million with a return based on cumulative commercial milestones and low-single digit royalties. Moderna expects to recognize the funding as a reduction in research and development expenses and will retain full rights and control of the Company's flu program. This funding does not result in any change to Moderna's 2024 research and development framework spending of approximately $4.5 billion.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.


Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

INDICATION (U.S.)

SPIKEVAX (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.

IMPORTANT SAFETY INFORMATION

• Do not administer to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.
• Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the vaccine.
• Postmarketing data demonstrate increased risks of myocarditis and pericarditis, particularly within 7 days following the second dose. The observed risk is higher among males under 40 years of age than among females and older males. The observed risk is highest in males 18 through 24 years of age.
• Syncope (fainting) may occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.
• Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to the vaccine.
• The vaccine may not protect all vaccine recipients.
• Adverse reactions reported in clinical trials following administration of the vaccine include pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, and erythema at the injection site, and rash.
• The vaccination provider is responsible for mandatory reporting of certain adverse events to the Vaccine Adverse Event Reporting System (VAERS) online at https://vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967.
• Please see the SPIKEVAX Full Prescribing Information . For information regarding authorized emergency uses of the Moderna COVID-19 Vaccine, please see the EUA Fact Sheet .

Spikevax ® is a registered trademark of Moderna. Fluzone ® is a registered trademark of Sanofi Pasteur. Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the advancement of Moderna's programs under clinical development; the timing for anticipated approvals of vaccine candidates; the efficacy, safety and tolerability of vaccine candidates; the total addressable markets for programs under development; the efficiencies and advantages of Moderna's mRNA platform; future capital allocation and financing efforts; and anticipated spending for R&D in 2024. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov . Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

Moderna Contacts

Media: Chris Ridley Head, Global Media Relations +1 617-800-3651 [email protected]

Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 [email protected]

SOURCE: Moderna, Inc.

Quick Links

• SEC Filings
• Investor FAQs
• Information Request Form

[email protected]

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Moderna, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Moderna to send you the requested Investor Email Alert updates.

Email Alert Sign Up Confirmation

Investor overview

Press releases

Media Center

Partnerships.

Strategic collaborators

Company culture

People behind the science

Join our team

Innovation Incubator

New venture labs

• Terms of Use
• Privacy Policy
• Contact Moderna

Got any suggestions?

We want to hear from you! Send us a message and help improve Slidesgo

Top searches

Trending searches

8 templates

solar eclipse

25 templates

ai technology

148 templates

55 templates

22 templates

Computer Virus Minitheme

Computer virus minitheme presentation, free google slides theme and powerpoint template.

Oh no! A virus has entered this template! Check your data protection settings and change all your passwords… and check out this modern computer virus minitheme, illustrated with viruses and bugs! Perfect for any cyber security-related presentation, all its slides are fully customizable to make your content shine and their color combination is professional yet edgy. Download the template for Google Slides or PowerPoint, edit them and get ready to present your IT content like never before!

Features of this template

• 100% editable and easy to modify
• 20 different slides to impress your audience
• Contains easy-to-edit graphics such as graphs, maps, tables, timelines and mockups
• Includes 500+ icons and Flaticon’s extension for customizing your slides
• Designed to be used in Google Slides and Microsoft PowerPoint
• 16:9 widescreen format suitable for all types of screens
• Includes information about fonts, colors, and credits of the resources used

How can I use the template?

Am I free to use the templates?

How to attribute?

Attribution required If you are a free user, you must attribute Slidesgo by keeping the slide where the credits appear. How to attribute?

Related posts on our blog.

How to Add, Duplicate, Move, Delete or Hide Slides in Google Slides

How to Change Layouts in PowerPoint

How to Change the Slide Size in Google Slides

Related presentations.

Premium template

Unlock this template and gain unlimited access

Register for free and start editing online